Literature DB >> 12533311

Peroxisome proliferator ameliorates endothelial dysfunction in a murine model of hyperhomocysteinemia.

Harpreet S Sood1, Matthew J Hunt, Suresh C Tyagi.   

Abstract

To test the hypothesis that endothelial dysfunction in hyperhomocysteinemia was due to increased levels of nitrotyrosine and matrix metalloproteinase (MMP) activity in response to antagonism of peroxisome proliferator-activated receptor-alpha (PPAR-alpha), cystathionine beta-synthase (CBS) -/+ mice were bred, tail tissue was analyzed for genotype by PCR, and tail vein blood was analyzed for homocysteine (Hcy) by spectrofluorometry. To induce PPAR-alpha, mice were administered 8 microg/ml of ciprofibrate (CF) and grouped: 1) wild type (WT), 2) WT + CF, 3) CBS, 4) CBS + CF (n = 6 in each group). In these four groups of mice, plasma Hcy was 3.0 +/- 0.2, 2.5 +/- 1.2, 15.2 +/- 2.6 (P < 0.05 compared with WT), 11.0 +/- 2.9 micromol/l. Mouse urinary protein was 110 +/- 11, 86 +/- 6, 179 +/- 13, 127 +/- 9 microg.day(-1). kg(-1) by Bio-Rad dye binding assay. Aortic nitrotyrosine was 0.099 +/- 0.012, 0.024 +/- 0.004, 0.132 +/- 0.024 (P < 0.01 compared with WT), 0.05 +/- 0.01 (scan unit) by Western analysis. MMP-2 activity was 0.053 +/- 0.010, 0.024 +/- 0.002, 0.039 +/- 0.009, 0.017 +/- 0.006 (scan unit) by zymography. MMP-9 was specifically induced in CBS -/+ mice and inhibited by CF treatment. Systolic blood pressure (SPB) was 90 +/- 2, 88 +/- 16, 104 +/- 8 (P < 0.05 compared with WT), 96 +/- 3 mmHg. Aortic wall stress [(SPB. radius(2)/wall thickness)/2(radius + wall thickness)] was 10.2 +/- 1.9, 9.7 +/- 0.2, 16.6 +/- 0.8 (P < 0.05 compared with WT), 13.1 +/- 2.1 dyn/cm(2). The results suggest that Hcy increased aortic wall stress by increasing nitrotyrosine and MMP-9 activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12533311     DOI: 10.1152/ajplung.00183.2002

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  9 in total

1.  Mesenteric vascular remodeling in hyperhomocysteinemia.

Authors:  C Munjal; S Givvimani; N Qipshidze; N Tyagi; J C Falcone; S C Tyagi
Journal:  Mol Cell Biochem       Date:  2010-11-13       Impact factor: 3.396

2.  3-Deazaadenosine mitigates arterial remodeling and hypertension in hyperhomocysteinemic mice.

Authors:  Alexander V Ovechkin; Neetu Tyagi; Utpal Sen; David Lominadze; Mesia M Steed; Karni S Moshal; Suresh C Tyagi
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-06-30       Impact factor: 5.464

3.  Pioglitazone treatment following spinal cord injury maintains acute mitochondrial integrity and increases chronic tissue sparing and functional recovery.

Authors:  Samir P Patel; David H Cox; Jenna L Gollihue; William M Bailey; Werner J Geldenhuys; John C Gensel; Patrick G Sullivan; Alexander G Rabchevsky
Journal:  Exp Neurol       Date:  2017-03-30       Impact factor: 5.330

4.  Cystathionine beta synthase gene dose dependent vascular remodeling in murine model of hyperhomocysteinemia.

Authors:  Neetu Tyagi; Natia Qipshidze; Utpal Sen; Walter Rodriguez; Alexander Ovechkin; Suresh C Tyagi
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2011-09-08

Review 5.  Ability of dietary factors to affect homocysteine levels in mice: a review.

Authors:  Christine Brütting; Pia Hildebrand; Corinna Brandsch; Gabriele I Stangl
Journal:  Nutr Metab (Lond)       Date:  2021-06-30       Impact factor: 4.169

6.  Hyperhomocysteinemia is associated with decreased apolipoprotein AI levels in normal healthy people.

Authors:  Ying Wang; Jia Liu; Yuliang Jiang; Heng Zhang; Song Leng; Guang Wang
Journal:  BMC Cardiovasc Disord       Date:  2016-01-13       Impact factor: 2.298

7.  Hyperhomocysteinemia and its relations to conventional risk factors for cardiovascular diseases in adult Nigerians: the REMAH study.

Authors:  Babangida S Chori; Benjamin Danladi; Bassey A Inyang; Michael P Okoh; Maxwell M Nwegbu; Adewale L Alli; Augustine N Odili
Journal:  BMC Cardiovasc Disord       Date:  2021-02-18       Impact factor: 2.298

8.  Role of C677T and A1298C MTHFR, A2756G MTR and -786 C/T eNOS gene polymorphisms in atrial fibrillation susceptibility.

Authors:  Betti Giusti; Anna Maria Gori; Rossella Marcucci; Ilaria Sestini; Claudia Saracini; Elena Sticchi; Francesca Gensini; Cinzia Fatini; Rosanna Abbate; Gian Franco Gensini
Journal:  PLoS One       Date:  2007-06-06       Impact factor: 3.240

9.  Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: the pleiotropic effects of folate supplementation.

Authors:  Melvin R Hayden; Suresh C Tyagi
Journal:  Nutr J       Date:  2004-05-10       Impact factor: 3.271

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.